Alkermes: proprietary sales up 31% in Q3 as orexin readouts near
Alkermes reported Q3 proprietary sales up 31% year on year to $417.3M and adjusted EBITDA of $120.1M, with six orexin study readouts expected within a year.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Alkermes (ALKS) posted third-quarter proprietary sales up 31% year on year, reaching $417.3 million. Adjusted EBITDA came in at $120.1 million. The company is directing this commercial strength toward its orexin pipeline, where six study readouts are expected over the coming year.
why it matters
For investors, the result shows the commercial business can fund several pipeline programs at once. The timing of the six readouts over the next year makes the orexin pipeline a key point to watch.
market impact
Alkermes shares: strong sales and EBITDA support interest in the company
tags
instruments
sources
- ALKS: Proprietary sales rose 31% as six orexin study readouts approach — TradingView, 3 November 2026 at 17:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗